[Renal injury during combination immunotherapy (ipilimumab + nivolumab) in patients with metastatic renal cell cancer who previously underwent nephrectomy].

A significant renal injury was seen during 28 weeks of follow-up in patients with metastatic RCC after nephrectomy receiving ipilimumab and nivolumab.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-03-01
Primary Topic
Renal cell carcinoma treatment
Type
article
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

[Renal injury during combination immunotherapy (ipilimumab + nivolumab) in patients with metastatic renal cell cancer who previously underwent nephrectomy].

Vozdvijenski M. ., Sen K, V Shpot E, Yu Nesterova O et al.
1 links
PubMed
Renal cell carcinoma treatment
article

[Renal injury during combination immunotherapy (ipilimumab + nivolumab) in patients with metastatic renal cell cancer who previously underwent nephrectomy].

Vozdvijenski M. ., Sen K, V Shpot E, Yu Nesterova O, Alexandra A Castro Stepanova Alexandra A
article en

Abstract

A significant renal injury was seen during 28 weeks of follow-up in patients with metastatic RCC after nephrectomy receiving ipilimumab and nivolumab.

PubMed(1)
Peoples' Friendship University of Russia (RU), Lomonosov Moscow State University (RU), Botkin Hospital (RU), Moscow State University (TJ), Moscow State Industrial University (RU)
Renal cell carcinoma treatment
OpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.